Why AstraZeneca Vietnam?
AstraZeneca was formed on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK – two companies with similar science-based cultures and a shared vision of the pharmaceutical industry.
The merger aimed to improve the combined companies’ ability to deliver long term growth and enduring shareholder value through:
Global power & reach in sales and marketing
- Ability to deliver the potential of existing and future products through the power and reach of a combined global sales and marketing resource
- Widespread class coverage in key therapy areas, such as cardiovascular and respiratory disease, due to complementary nature of products
- Major primary care presence, particularly in gastrointestinal, cardiovascular and respiratory medicine
- Leading position in a number of specialist/hospital markets, including oncology and anaesthesia
Stronger R&D platform for innovation-led growth
- Substantial research and development (R&D) expenditure
- Strong combined development pipeline
- Potential for further strengthening of the pipeline by enhanced discovery and development capability through greater scale and focus on selected areas and technologies
Greater financial strategic flexibility
- Financial strength and scale to give AstraZeneca's management greater strategic flexibility to drive long-term earnings growth
- .ubstantial operational efficiencies resulting in cost savings
Cardiovascular & Metabolic
CV disease remains the greatest risk to life for adults, accounting for 17 million deaths worldwide each year. Diabetes affects over 340 million people.
More than 450 million people worldwide are affected by mental, neurological or behavioural problems and the rate is steadily rising.
In the West (i.e. Europe and North America) between 10-20% of adults suffer from GERD. The prevalence of GERD in Asia is lower, but increasing.
Cancer claims over 7 million lives every year and the number continues to rise. Deaths are estimated to reach 13 million by 2030.
World demand for antibiotics remains high, due to escalating resistance and the increased risk of serious infections in both immunosuppressed patients and ageing populations.
Some 235 million people suffer from asthma. It is the most common chronic disease among children.